ANNOUNCEMENT: Goodbody Health subsidiary granted Home Office controlled drugs licence

Goodbody Health Inc.
(“Goodbody” or “Goodbody Health” the “Company” or the “Group”)

11th April 2022

Goodbody Health subsidiary granted Home Office controlled drugs licence 

Goodbody Health (AQSE: GDBY) is pleased to announce that its subsidiary, PhytoVista Laboratories, has been granted a controlled drugs licence that allows the company to handle up to Schedule 1 Controlled Drugs. This comes as the UK authorities look to the regulation of the UK consumer cannabinoid product testing infrastructure ahead of wider compliance within the industry.

The FSA have released the list of products associated with a credible Novel Food application and we expect the industry to continue to move to a fully regulated market that the Consumer can trust.

PhytoVista is one of a small number of laboratories accredited by the UK National Accreditation Service (UKAS) with extended provisions to carry out these specialist activities.

Geremy Thomas, Executive Chairman, said: “After significant hard work and investment, we are delighted to be recognised and awarded this highly controlled and regulated licence. PhytoVista continues to be a material part of the Government’s commitment to create a compliant, consumer cannabinoid industry.”

For further information:

Marc Howells
Chief Executive Officer
Goodbody Health Inc.
+44 (0) 20 7971 1255
[email protected]
www.goodbodyhealth.com

AQSE Growth Market Corporate Advisor
Corporate Finance
Antonio Bossi / George Morgan
Arden Partners Ltd
+ 44 (0) 20 7614 5900

Anne Tew
Chief Financial Officer
Goodbody Health Inc.
+44 (0) 20 7971 1255
[email protected]
www.goodbodyhealth.com

Share on

Share on linkedin
Share on twitter
Share on facebook
Share on email

Published on

Categories